Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Northwest Biotherapeutics, Inc. (NWBO)
USD0.16
-0.01 (-4.36%)
US OTC Healthcare Biotechnology
Address
4800 Montgomery Lane 20814
Bethesda, MD, US
Bethesda, MD, US
CEO
Linda F. Powers
Website
nwbio.com
IPO
2001-12-14
CIK 1072379 ISIN US66737P6007
Description
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.16
-0.01 (-4.36%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
-0.66
Float Shares
1.57B
Free Float %
97.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20% | +5.21% | +28.50% | +8.37% | +9.31% | +10.99% | -13.41% | -57.85% | -87.05% | -71.75% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
0.16
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-28.03
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-0.3% Q1'26: +31.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+38.5% ★ Q1'26: +85.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,772.2% Q1'26: -2,532.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-4,347.9% Q1'26: -2,206.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-421.4% Q1'26: -180.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+17.3% Q1'26: +16.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.13× Q1'26: -1.47× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|
| Revenue |
412.0K
est: 1.37B (-100.0%)
|
1.56M
1.56M – 1.56M
-99.9% YoY
|
| EBITDA |
-24.63M
est: -824.02M (+97.0%)
|
-937.4K
-937.4K – -937.4K
+99.9% YoY
|
| EBIT |
-25.92M
est: -824.02M (+96.9%)
|
-937.4K
-937.4K – -937.4K
+99.9% YoY
|
| Net Income |
-35.79M
|
-72.83M
-72.83M – -72.83M
|
| SGA |
27.02M
est: 36.90B (-99.9%)
|
36.21M
36.21M – 36.21M
-99.9% YoY
|
| EPS |
-0.12
|
-0.05
-0.05 – -0.05
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-45.20M
OE per share TTM
-0.03
Owner's Yield
-12.27%
Maintenance CapEx ratio
323.44%
Maint CapEx / Avg PPE
1,108.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
5
Total invested
83.2K
Insider transactions (90d)
0
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Woodford Investment Management LLP | 25.92M | 22.80% | — | 24.82M | — | 10.00 | PN | United Kingdom | 2016-07-28 | ↗ |
| 2 | Neil Woodford | 24.82M | 8.40% | — | 24.82M | — | 24.82M | IN | United Kingdom | 2017-09-11 | ↗ |
| 3 | Woodford Investment Management Ltd | 24.82M | 8.40% | — | 24.82M | — | 24.82M | FI | United Kingdom | 2017-09-11 | ↗ |
| 4 | Investment Management Ltd | 24.82M | 4.80% | — | 24.82M | — | 24.82M | FI | Kingdom | 2019-02-14 | ↗ |
| 5 | Woodford | 24.82M | 4.80% | — | 24.82M | — | 24.82M | IN | Kingdom | 2019-02-14 | ↗ |
| 6 | CF Woodford Equity Income Fund | 18.32M | 11.90% | — | 18.32M | — | — | OO | United Kingdom | 2017-01-10 | ↗ |
| 7 | Woodford Equity Income Fund | 18.32M | 5.80% | — | 18.32M | — | — | FI | Kingdom | 2018-02-13 | ↗ |
| 8 | LF Woodford Equity Income Fund | 18.32M | 3.50% | — | 18.32M | — | 18.32M | FI | United Kingdom | 2019-02-14 | ↗ |
| 9 | CVI Investments, Inc. | 11.51M | 3.50% | — | 11.51M | — | 11.51M | CO | Cayman Islands | 2018-02-09 | ↗ |
| 10 | Heights Capital Management, Inc. | 11.51M | 3.50% | — | 11.51M | — | 11.51M | CO | Delaware | 2018-02-09 | ↗ |
| 11 | Daniel B. Asher | 11.47M | 3.60% | — | 11.47M | — | 11.47M | HC, IN | United States of America | 2018-02-13 | ↗ |
| 12 | Intracoastal Capital LLC | 11.47M | 3.60% | — | 11.47M | — | 11.47M | OO | United States of America | 2018-02-13 | ↗ |
| 13 | Mitchell P. Kopin | 11.47M | 3.60% | — | 11.47M | — | 11.47M | HC, IN | United States of America | 2018-02-13 | ↗ |
| 14 | 6.1% (see Item 4) | 9.69M | 6.10% | — | 9.69M | — | 8.24M | OO | United States of America | 2016-12-30 | ↗ |
| 15 | 10. | 6.61M | 4.00% | — | 6.61M | — | 6.61M | HC, IN | United States of America | 2017-03-24 | ↗ |
| 16 | BARCLAYS GLOBAL INVESTORS, NA. | 4.53M | 5.59% | — | 11.97M | — | 11.97M | BK | United States of America | 2017-03-24 | ↗ |
| 17 | Dennis Mehiel | 4.07M | 4.20% | — | — | 4.02M | 50.0K | IN | United States | 2016-01-27 | ↗ |
| 18 | Four M Purchasers LLC | 2.15M | 2.20% | — | — | 2.15M | — | OO | United States | 2016-01-27 | ↗ |
| 19 | Prudential Financial, Inc. | 1.95M | 8.70% | — | 14.98M | — | 14.98M | HC | Cayman Islands | 2017-06-01 | ↗ |
| 20 | Capital Ventures International | 1.04M | 2.30% | — | 1.04M | — | 1.04M | CO | Cayman Islands | 2014-02-13 | ↗ |
| 21 | Mercury Real Estate Advisors LLC | 289.3K | 5.10% | 4.00 | 4.00 | 4.00 | 4.00 | OO | Delaware | 2014-02-13 | ↗ |
| 22 | The Karen L. Mehiel 2012 Siblings Trust | 50.0K | 0.10% | — | — | 50.0K | — | OO | United States | 2016-01-27 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
5
+0 vs prev Q
New positions
1
Closed positions
1
Increased
2
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | KELLEHER FINANCIAL ADVISORS | 200.0K +200.0K (+100.0%) | 41.3K +41.3K (+100.0%) | 0.01% +0.014 pp | 0.01% +0.011 pp | USD0.21 +0.0% | 1 qtrs NEW |
| 2 | VSM WEALTH ADVISORY, LLC | 80.6K +— (+0.0%) | 16.6K +1.6K (+10.9%) | 0.01% +0.000 pp | 0.01% +0.001 pp | USD0.26 -19.2% | 6 qtrs — |
| 3 | OPUS CAPITAL GROUP, LLC | 60.2K +— (+0.0%) | 12.0K -2.0K (-14.3%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD0.92 -77.2% | 28 qtrs — |
| 4 | ETHOS FINANCIAL GROUP, LLC | 39.1K +10.7K (+37.8%) | 8.1K +1.6K (+24.4%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.32 -34.4% | 9 qtrs — |
| 5 | WILLIAMS JONES WEALTH MANAGEMENT, LLC. | 25.0K -2.0K (-7.4%) | 5.2K -1.0K (-16.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.31 -32.3% | 27 qtrs — |
| 6 | ADVISORS MANAGEMENT GROUP INC /ADV | — -10.3K (-100.0%) | — -2.0K (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 14 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
1.66M
Cash buys
—
Cash sales
1.00
Net activity
-1,657,895
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-29 | BOYNTON ALTON L | Director / Officer | G-Gift | D | STOCK OPTIONS | 1,000,000 | 0.23 | 230.0K | 967,065 | — | ↗ |
| 2024-08-09 | BOSCH MARNIX L | Officer | G-Gift | D | STOCK OPTIONS | 3,000,000 | 0.35 | 1.05M | 4,549,157 | — | ↗ |
| 2024-08-08 | BOYNTON ALTON L | Director / Officer | G-Gift | D | STOCK OPTIONS | 1,000,000 | 0.23 | 230.0K | 1,967,065 | — | ↗ |
| 2024-07-26 | MALIK NAVID | Director | S-Sale | D | Stock Option | 657,895 | 0.23 | 151.3K | 23,339,393 | — | ↗ |
| 2023-11-17 | MALIK NAVID | Director | S-Sale | A | Common Stock | 150,000 | 0.82 | 123.5K | 295,000 | — | ↗ |
| 2023-11-16 | MALIK NAVID | Director | S-Sale | A | Common Stock | 125,000 | 0.84 | 104.4K | 445,000 | — | ↗ |
| 2023-04-04 | BOYNTON ALTON L | Director / Officer | G-Gift | D | STOCK OPTIONS | 6,794,191 | 0.35 | 2.38M | 2,967,065 | — | ↗ |
| 2023-04-03 | BOSCH MARNIX L | Officer | A-Award | A | Common Stock | 119,355 | 0.25 | 29.8K | 119,355 | — | ↗ |
| 2022-12-06 | BOYNTON ALTON L | Officer | G-Gift | D | COMMON STOCK OPTIONS | 4,500,000 | 0.35 | 1.58M | 9,761,256 | — | ↗ |
| 2022-12-01 | JASINOWSKI JERRY J | Director | A-Award | A | Series C Convertible Preferred Stock | 28,235 | 21.25 | 600.0K | 28,235 | — | ↗ |
| 2022-05-26 | BOYNTON ALTON L | Officer | G-Gift | D | COMMON STOCK OPTIONS | 4,900,000 | 0.23 | 1.13M | 9,761,256 | — | ↗ |
| 2021-01-19 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Employee Stock Option (Right to Buy) | 3,402,935 | 0.25 | 850.7K | 0 | — | ↗ |
| 2020-10-14 | Powers Linda F | Director / Officer / 10% Owner | G-Gift | D | Options to purchase Common Stock | 3,000,000 | 0.25 | 750.0K | 29,558,724 | — | ↗ |
| 2020-07-02 | Powers Linda F | Director / Officer / 10% Owner | A-Award | A | Warrants to purchase Common Stock | 15,249,474 | 0.21 | 3.20M | 15,249,474 | — | ↗ |
| 2020-07-02 | Goldman Leslie J. | Officer | A-Award | A | Options to purchase Common Stock, par value $0.001 | 1,315,566 | 0.25 | 328.9K | 1,315,566 | — | ↗ |
| 2020-07-02 | BOYNTON ALTON L | Director / Officer | A-Award | A | Options to purchase Common Stock, par value $0.001 | 605,160 | 0.25 | 151.3K | 605,160 | — | ↗ |
| 2020-07-02 | BOSCH MARNIX L | Officer | A-Award | A | Options to purchase Common Stock, par value $0.001 | 7,549,157 | 0.25 | 1.89M | 7,549,157 | — | ↗ |
| 2020-04-30 | Powers Linda F | Officer | J-Other | A | Warrants | 29,411,760 | 0.22 | 6.47M | 29,411,760 | — | ↗ |
| 2020-02-03 | JASINOWSKI JERRY J | Director | A-Award | A | Common Stock | 526,316 | 0.19 | 100.0K | 1,891,347 | — | ↗ |
| 2019-12-09 | DAVIS JEAN M. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-28 | Powers Linda F | Director / Officer / 10% Owner | S-Sale | D | Restricted Common Stock, par value $0.001 | 804,146 | 0.17 | 136.7K | 0 | — | ↗ |
| 2018-12-27 | Powers Linda F | Director / Officer / 10% Owner | S-Sale | D | Restricted Common Stock, par value $0.001 | 3,558,639 | 0.17 | 605.0K | 29,411,760 | — | ↗ |
| 2018-05-28 | Powers Linda F | Director | A-Award | A | Options to purchase Common Stock, par value $0.001 | 39,200,000 | 0.23 | 9.02M | 39,200,000 | — | ↗ |
| 2018-05-28 | MALIK NAVID | Director | A-Award | A | Options to purchase Common Stock, par value $0.001 | 9,065,000 | 0.23 | 2.08M | 9,065,000 | — | ↗ |
| 2018-05-28 | JASINOWSKI JERRY J | Director | A-Award | A | Options to purchase Common Stock, par value $0.001 | 4,900,000 | 0.23 | 1.13M | 4,900,000 | — | ↗ |
| 2018-05-28 | Goldman Leslie J. | Officer | A-Award | A | Options to purchase Common Stock, par value $0.001 | 24,500,000 | 0.23 | 5.64M | 24,500,000 | — | ↗ |
| 2018-05-28 | BOYNTON ALTON L | Director | A-Award | A | Options to purchase Common Stock, par value $0.001 | 4,900,000 | 0.23 | 1.13M | 11,270,000 | — | ↗ |
| 2018-05-28 | BLACK COFER | Director | A-Award | A | Options to purchase Common Stock, par value $0.001 | 1,715,000 | 0.23 | 394.5K | 1,715,000 | — | ↗ |
| 2018-03-19 | Powers Linda F | Director / Officer | A-Award | A | Class D-2 Warrants | 869,565 | 0.30 | 260.9K | 869,565 | — | ↗ |
| 2018-03-14 | Powers Linda F | Director / Officer | A-Award | A | Class D-2 Warrants | 8,695,652 | 0.30 | 2.61M | 8,695,652 | — | ↗ |
| 2018-03-12 | Powers Linda F | Director / Officer | J-Other | A | Class D-1 Warrants | 29,411,760 | 0.22 | 6.47M | 29,411,760 | — | ↗ |
| 2017-06-13 | BOYNTON ALTON L | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 3,402,935 | 0.25 | 850.7K | 3,402,935 | — | ↗ |
| 2017-06-13 | BOSCH MARNIX L | Officer | M-Exempt | A | Employee Stock Option (Right to Buy) | 7,940,182 | 0.25 | 1.99M | 7,940,182 | — | ↗ |
| 2016-01-25 | BLACK COFER | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-01-25 | BAYH SUSAN B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-11-05 | Woodford Investment Management LLP | 10% Owner | — | I | Common stock, $0.001 par value per share | 0 | 0.00 | — | 25,915,937 | — | ↗ |
| 2015-06-30 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 | 650,000 | 4.00 | 2.60M | 19,578,482 | — | ↗ |
| 2014-09-15 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock | 149,502 | 5.02 | 750.5K | 20,228,482 | — | ↗ |
| 2014-09-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 319,554 | 4.00 | 1.28M | 319,554 | — | ↗ |
| 2014-08-27 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock | 145,068 | 5.17 | 750.0K | 19,738,876 | — | ↗ |
| 2014-08-01 | Farmer Robert A | Director | P-Purchase | A | Common Stock, par value $0.001 | 3,013 | 5.60 | 16.9K | 135,417 | — | ↗ |
| 2014-08-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 275,110 | 4.00 | 1.10M | 275,110 | — | ↗ |
| 2014-07-17 | Cognate Bioservices, Inc. | 10% Owner | J-Other | A | Warrants | 3,220,235 | 4.00 | 12.88M | 3,220,235 | — | ↗ |
| 2014-07-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 398,439 | 4.00 | 1.59M | 398,439 | — | ↗ |
| 2014-06-30 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 281,250 | 4.00 | 1.13M | 281,250 | — | ↗ |
| 2014-06-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 192,600 | 4.00 | 770.4K | 192,600 | — | ↗ |
| 2014-05-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 170,985 | 4.00 | 683.9K | 170,985 | — | ↗ |
| 2014-04-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 144,766 | 4.00 | 579.1K | 144,766 | — | ↗ |
| 2014-03-07 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock | 120,370 | 3.64 | 438.1K | 16,957,525 | — | ↗ |
| 2014-03-01 | Cognate Bioservices, Inc. | Director | P-Purchase | A | Common Stock | 550,219 | 2,200,876.00 | 1.21T | 19,883,944 | — | ↗ |
| 2014-02-28 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 143,528 | 4.00 | 574.1K | 143,528 | — | ↗ |
| 2014-02-08 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock | 79,630 | 3.09 | 246.1K | 16,821,617 | — | ↗ |
| 2014-02-07 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock | 132,540 | 3.09 | 409.5K | 16,901,247 | — | ↗ |
| 2014-02-04 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock | 233,344 | 3.21 | 749.0K | 17,033,787 | — | ↗ |
| 2014-02-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Common Stock | 500,000 | 0.00 | — | 16,980,076 | — | ↗ |
| 2014-01-31 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock | 233,344 | 3.21 | 749.0K | 16,480,076 | — | ↗ |
| 2014-01-17 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 138,600 | 4.00 | 554.4K | 138,600 | — | ↗ |
| 2014-01-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Common Stock | 238,248 | 1,012,992.36 | 241.34B | 11,612,054 | — | ↗ |
| 2013-12-31 | Cognate Bioservices, Inc. | 10% Owner | J-Other | A | Common Stock | 1,330,057 | 5,320,228.00 | 7.08T | 11,373,806 | — | ↗ |
| 2013-12-17 | MALIK NAVID | Director | P-Purchase | A | Common Stock, par value $0.001 | 10,000 | 0.00 | 10.00 | 10,000 | — | ↗ |
| 2013-12-04 | Farmer Robert A | Director | P-Purchase | A | Common Stock, par value $0.001 | 132,404 | 5.60 | 741.5K | 132,404 | — | ↗ |
| 2013-12-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Common stock, par value $0.001 per share ("Common Stock") | 277,199 | 1,108,797.24 | 307.36B | 10,043,749 | — | ↗ |
| 2013-11-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 128,719 | 4.00 | 514.9K | 128,719 | — | ↗ |
| 2013-10-31 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Common Stock | 223,042 | 892,569.00 | 199.08B | 9,509,111 | — | ↗ |
| 2013-07-31 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 1,451,036 | 3.20 | 4.64M | 1,451,036 | — | ↗ |
| 2012-12-29 | Powers Linda F | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 59,405 | 0.00 | — | 10,750,587 | — | ↗ |
| 2012-12-12 | Powers Linda F | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 6,468,153 | 10,688,615.00 | 69.14T | 10,809,992 | — | ↗ |
| 2012-11-30 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 374,670 | 3.20 | 1.20M | 374,670 | — | ↗ |
| 2012-11-19 | Farmer Robert A | Director | X-InTheMoney | A | Warrants | 8,352 | 6.40 | 53.5K | 8,352 | — | ↗ |
| 2012-10-18 | JASINOWSKI JERRY J | Director | P-Purchase | A | Common Stock, par value $0.001 | 35,715 | 5.60 | 200.0K | 35,715 | — | ↗ |
| 2012-10-16 | Cognate Bioservices, Inc. | 10% Owner | C-Conversion | A | Common stock, par value $0.001 per share ("Common Stock") | 2,118,761 | 0.00 | — | 2,675,318 | — | ↗ |
| 2012-10-10 | JASINOWSKI JERRY J | Director | P-Purchase | A | Common Stock, par value $0.001 | 43,602 | 4.80 | 209.3K | 79,317 | — | ↗ |
| 2012-08-15 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 1,500,000 | 0.40 | 600.0K | 1,500,000 | — | ↗ |
| 2012-08-08 | JASINOWSKI JERRY J | Director | X-InTheMoney | A | Warrants | 17,857 | 5.60 | 100.0K | 49,107 | — | ↗ |
| 2012-07-24 | Powers Linda F | Officer | G-Gift | D | Common Stock | 950,000 | 0.00 | — | 11,385,824 | — | ↗ |
| 2012-03-27 | JASINOWSKI JERRY J | Director | X-InTheMoney | A | Warrants | 31,250 | 6.40 | 200.0K | 31,250 | — | ↗ |
| 2012-03-06 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 4,470,938 | 0.57 | 2.55M | 4,470,938 | — | ↗ |
| 2012-02-09 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 4,687,500 | 0.57 | 2.67M | 761,240 | — | ↗ |
| 2011-12-29 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 250,000 | 0.40 | 100.0K | 250,000 | — | ↗ |
| 2011-11-01 | Cognate Bioservices, Inc. | 10% Owner | C-Conversion | A | Common Stock | 750,000 | 100,000.00 | 75.00B | 9,854,913 | — | ↗ |
| 2011-10-28 | Cognate Bioservices, Inc. | Director | P-Purchase | A | Common Stock | 257,439 | 1,029,755.88 | 265.10B | 9,766,550 | — | ↗ |
| 2011-09-19 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 210,935 | 0.00 | — | 2,894,091 | — | ↗ |
| 2011-09-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 909,000 | 0.75 | 681.8K | 909,000 | — | ↗ |
| 2011-06-21 | BOYNTON ALTON L | Director / Officer | A-Award | A | Option | 1,376,562 | 0.66 | 908.5K | 2,819,000 | — | ↗ |
| 2011-06-08 | Cognate Bioservices, Inc. | 10% Owner | A-Award | A | Options | 14,220,000 | 10.56 | 150.16M | 14,220,000 | — | ↗ |
| 2011-04-07 | Powers Linda F | Director / 10% Owner | G-Gift | D | Common Stock | 950,000 | 0.00 | — | 48,774,998 | — | ↗ |
| 2011-03-06 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 60,000 | 0.00 | — | 1,975,440 | — | ↗ |
| 2011-02-02 | Cognate Bioservices, Inc. | 10% Owner | S-Sale | D | Common Stock | 860,000 | 1.08 | 928.8K | 7,088,246 | — | ↗ |
| 2010-12-17 | BOYNTON ALTON L | Director / Officer | A-Award | A | Common Stock | 243,432 | 0.61 | 148.5K | 2,410,866 | — | ↗ |
| 2010-10-09 | Cognate Bioservices, Inc. | 10% Owner | J-Other | D | Common Stock | 120,000 | 0.17 | 20.4K | 7,948,246 | — | ↗ |
| 2010-10-01 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Promissory Note | 1,200,000 | 0.75 | 900.0K | 1,200,000 | — | ↗ |
| 2010-09-30 | Cognate Bioservices, Inc. | 10% Owner | J-Other | A | Warrants | 14,296,039 | 0.60 | 8.58M | 14,296,039 | — | ↗ |
| 2010-09-23 | BOYNTON ALTON L | Director / Officer | E-ExpireShort | D | Option | 375,426 | 0.60 | 225.3K | 1,442,438 | — | ↗ |
| 2010-09-01 | Powers Linda F | Director / 10% Owner | G-Gift | D | Common Stock | 950,000 | 0.00 | — | 32,840,177 | — | ↗ |
| 2010-08-12 | Cognate Bioservices, Inc. | 10% Owner | J-Other | D | Common Stock | 2,250,000 | 0.62 | 1.40M | 8,068,246 | — | ↗ |
| 2010-07-31 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Common Stock | 8,466 | 0.20 | 1.7K | 10,318,246 | — | ↗ |
| 2010-07-02 | Cognate Bioservices, Inc. | 10% Owner | A-Award | A | Common Stock | 866,667 | 0.75 | 650.0K | 3,439,377 | — | ↗ |
| 2010-05-24 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 260,007 | 0.00 | — | 1,875,129 | — | ↗ |
| 2010-01-04 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 82,280 | 0.00 | — | 1,874,355 | — | ↗ |
| 2009-12-09 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 419,270 | 0.00 | — | 2,234,627 | — | ↗ |
| 2009-11-27 | BOYNTON ALTON L | Director / Officer | A-Award | A | Convertible Note | 231,770 | 0.20 | 46.4K | 2,612,163 | — | ↗ |
| 2009-11-07 | BOYNTON ALTON L | Director / Officer | C-Conversion | D | Convertible Note | 419,270 | 0.20 | 83.9K | 2,380,293 | — | ↗ |
| 2009-10-14 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 150,083 | 0.00 | — | 1,961,123 | — | ↗ |
| 2009-09-30 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Common Stock | 1,762,500 | 0.20 | 352.5K | 10,309,780 | — | ↗ |
| 2009-09-28 | Cognate Bioservices, Inc. | 10% Owner | J-Other | A | Common Stock | 2,763,691 | 0.20 | 552.7K | 8,547,280 | — | ↗ |
| 2009-08-21 | BOYNTON ALTON L | Director / Officer | A-Award | A | Option | 1,430,486 | 0.55 | 786.8K | 2,830,016 | — | ↗ |
| 2009-06-30 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | 6% Convertible Promissory Notes | 0 | 0.20 | — | 0 | — | ↗ |
| 2009-01-01 | BOYNTON ALTON L | Director / Officer | D-Return | D | Option | 1,430,486 | 0.60 | 858.3K | 1,399,530 | — | ↗ |
| 2008-12-22 | Cognate Bioservices, Inc. | 10% Owner | P-Purchase | A | Warrants | 132,500 | 0.40 | 53.0K | 132,500 | — | ↗ |
| 2008-08-19 | Powers Linda F | Director | P-Purchase | A | Promissory Note | 0 | 1,000,000.00 | — | 0 | — | ↗ |
| 2007-12-31 | BOYNTON ALTON L | Director / Officer | A-Award | A | Option | 2,807,048 | 0.60 | 1.68M | 2,830,016 | — | ↗ |
| 2007-10-01 | DEASEY ANTHONY P | Director / Officer | A-Award | A | Stock Option | 769,208 | 2.40 | 1.85M | 769,208 | — | ↗ |
| 2007-06-22 | Toucan Capital Fund II, LP | 10% Owner | J-Other | A | Common Stock | 4,287,851 | 0.00 | — | 19,299,486 | — | ↗ |
| 2007-06-22 | Harris Steve | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-06-01 | Toucan Partners, LLC | 10% Owner | P-Purchase | A | Series A-1 Preferred Stock Warrant | 3,408,833 | 1.60 | 5.45M | 6,471,333 | — | ↗ |
| 2007-03-28 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 1,000,000 | 0.00 | — | 3,046,000 | — | ↗ |
| 2007-01-01 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 550,000 | 0.00 | — | 4,046,000 | — | ↗ |
| 2006-12-15 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 4,596,800 | — | ↗ |
| 2006-05-17 | BOYNTON ALTON L | Director / Officer | G-Gift | D | Common Stock | 240,000 | 0.25 | 60.0K | 4,646,800 | — | ↗ |
| 2006-04-17 | Toucan Capital Fund II, LP | 10% Owner | C-Conversion | A | Series A-1 Cumulative Convertible Preferred Stock | 4,816,863 | 0.00 | — | 4,816,863 | — | ↗ |
| 2006-03-29 | Toucan Partners, LLC | 10% Owner | J-Other | A | Warrant | 3,000,000 | 0.00 | — | 3,000,000 | — | ↗ |
| 2006-03-18 | JOHNSTON JIM D | Officer | — | D | Stock Option (Right to Buy) | 25,000 | 0.21 | 5.3K | 0 | — | ↗ |
| 2005-11-14 | Toucan Partners, LLC | 10% Owner | — | D | Warrant | 4,000,000 | 0.00 | — | 0 | — | ↗ |
| 2005-11-14 | Powers Linda F | 10% Owner | P-Purchase | A | Warrant | 4,000,000 | 0.00 | — | 4,000,000 | — | ↗ |
| 2005-09-30 | Robertson Bruce C | 10% Owner | J-Other | D | 10% Convertible Secured Promissory Notes | 0 | 0.04 | — | 0 | — | ↗ |
| 2005-09-07 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | Warrant | 5,000,000 | 0.00 | — | 5,000,000 | — | ↗ |
| 2005-07-26 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | Warrant | 5,000,000 | 0.00 | — | 5,000,000 | — | ↗ |
| 2005-06-16 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | 10% Convertible Secured Promissory Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-05-13 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | Warrant | 4,500,000 | 0.00 | — | 4,500,000 | — | ↗ |
| 2004-12-27 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | Warrant | 2,500,000 | 0.00 | — | 2,500,000 | — | ↗ |
| 2004-11-10 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | Warrant | 5,000,000 | 0.00 | — | 5,000,000 | — | ↗ |
| 2004-10-22 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | Warrant | 5,000,000 | 0.00 | — | 5,000,000 | — | ↗ |
| 2004-07-30 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | Warrant | 20,000,000 | 0.00 | — | 20,000,000 | — | ↗ |
| 2004-06-11 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | Warrant | 0 | 0.01 | — | 66,000,000 | — | ↗ |
| 2004-05-12 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | 10% Convertible Promissory Notes | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-05-07 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | 10% Convertible Promissory Notes | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-04-29 | Toucan Capital Fund II, LP | 10% Owner | P-Purchase | A | 10% Convertible Promissory Notes | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-04-26 | Toucan Capital Fund II, LP | 10% Owner | — | I | Warrant | 36,000,000 | 0.01 | 360.0K | 0 | — | ↗ |
| 2003-12-16 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 1,891,937 | — | ↗ |
| 2003-10-27 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 1,906,502 | — | ↗ |
| 2003-10-20 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 1,921,067 | — | ↗ |
| 2003-10-14 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 1,935,632 | — | ↗ |
| 2003-10-10 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 1,950,197 | — | ↗ |
| 2003-09-29 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 1,964,762 | — | ↗ |
| 2003-09-22 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.28 | 4.1K | 1,979,327 | — | ↗ |
| 2003-09-15 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 1,993,892 | — | ↗ |
| 2003-09-12 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 2,008,457 | — | ↗ |
| 2003-09-02 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 2,023,022 | — | ↗ |
| 2003-08-27 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 2,037,587 | — | ↗ |
| 2003-08-12 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 2,052,152 | — | ↗ |
| 2003-08-04 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.31 | 4.5K | 2,066,717 | — | ↗ |
| 2003-07-28 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.32 | 4.7K | 2,081,282 | — | ↗ |
| 2003-07-21 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.31 | 4.5K | 2,095,847 | — | ↗ |
| 2003-07-14 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.38 | 5.5K | 2,110,412 | — | ↗ |
| 2003-07-07 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.34 | 5.0K | 2,124,977 | — | ↗ |
| 2003-06-30 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.39 | 5.7K | 2,139,542 | — | ↗ |
| 2003-06-23 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.27 | 3.9K | 2,154,107 | — | ↗ |
| 2003-06-16 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.26 | 3.8K | 2,168,672 | — | ↗ |
| 2003-06-09 | NORTHWEST HOSPITAL | 10% Owner | S-Sale | D | Common Stock | 14,565 | 0.25 | 3.6K | 2,183,237 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-24.0K
Shares Outstanding
1.61B
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Linda F. Powers Chairperson, President & Chief Executive Officer, Chief Financial and Accounting Officer | 925.0K | 300.0K | — | — | — | — | 1.23M | 0.00% | ↗ |
| 2 | 2024 | Leslie Goldman Former Senior Vice President and General Counsel | 725.0K | 250.0K | — | — | — | — | 975.0K | 0.00% | ↗ |
| 3 | 2024 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 453.6K | 180.0K | — | — | — | — | 633.6K | 0.00% | ↗ |
| 4 | 2023 | Linda F. Powers Chairperson, President & Chief Executive Officer, Chief Financial and Accounting Officer | 925.0K | 300.0K | — | — | — | — | 1.23M | 0.00% | ↗ |
| 5 | 2023 | Leslie Goldman Former Senior Vice President and General Counsel | 725.0K | 250.0K | — | — | — | — | 975.0K | 0.00% | ↗ |
| 6 | 2023 | Linda F. Powers Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer | 925.0K | — | — | — | — | — | 925.0K | 0.00% | ↗ |
| 7 | 2023 | Leslie Goldman Senior Vice President, General Counsel | 725.0K | — | — | — | — | — | 725.0K | 0.00% | ↗ |
| 8 | 2023 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 453.6K | 180.0K | — | — | — | — | 633.6K | 0.00% | ↗ |
| 9 | 2023 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 10 | 2022 | Linda F. Powers Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer | 700.0K | 400.0K | — | — | — | — | 1.10M | 0.00% | ↗ |
| 11 | 2022 | Leslie Goldman Senior Vice President, General Counsel | 525.0K | 300.0K | — | — | — | — | 825.0K | 0.00% | ↗ |
| 12 | 2022 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 397.5K | 200.0K | — | — | — | — | 597.5K | 0.00% | ↗ |
| 13 | 2022 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 350.0K | 100.0K | — | — | — | — | 450.0K | 0.00% | ↗ |
| 14 | 2021 | Linda F. Powers Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer | 700.0K | 300.0K | — | — | — | — | 1.00M | 0.00% | ↗ |
| 15 | 2021 | Leslie Goldman Senior Vice President,General Counsel and Business Development | 525.0K | 200.0K | — | — | — | — | 725.0K | 0.00% | ↗ |
| 16 | 2021 | Leslie Goldman Senior Vice President, General Counsel | 525.0K | 200.0K | — | — | — | — | 725.0K | 0.00% | ↗ |
| 17 | 2021 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 442.5K | 125.0K | — | — | — | — | 567.5K | 0.00% | ↗ |
| 18 | 2021 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 350.0K | 75.0K | — | — | — | — | 425.0K | 0.00% | ↗ |
| 19 | 2020 | Linda F. Powers Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer | 700.0K | — | — | 17.32M | — | — | 18.02M | 96.11% | ↗ |
| 20 | 2020 | Leslie Goldman Senior Vice President,General Counsel and Business Development | 525.0K | — | — | 10.55M | — | — | 11.07M | 95.26% | ↗ |
| 21 | 2020 | Leslie Goldman Senior Vice President, General Counsel and Business Development | 525.0K | — | — | 10.55M | — | — | 11.07M | 95.26% | ↗ |
| 22 | 2020 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 480.0K | — | — | 7.49M | — | — | 7.97M | 93.98% | ↗ |
| 23 | 2019 | Linda F. Powers Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer | 502.0K | 300.0K | — | — | — | — | 802.0K | 0.00% | ↗ |
| 24 | 2019 | Linda F. Powers Chairperson, President Chief Executive Officer | 502.0K | 100.0K | — | — | — | — | 602.0K | 0.00% | ↗ |
| 25 | 2019 | Leslie Goldman Senior Vice President, General Counsel and Business Development | 375.0K | 200.0K | — | — | — | — | 575.0K | 0.00% | ↗ |
| 26 | 2019 | Leslie Goldman Senior Vice President,General Counsel and Business Development | 375.0K | 200.0K | — | — | — | — | 575.0K | 0.00% | ↗ |
| 27 | 2019 | Jean M. Davis Chief Financial Officer, Chief Accounting Officer and Interim Chief Information Officer | 16.0K | — | — | 500.0K | — | — | 516.0K | 96.90% | ↗ |
| 28 | 2019 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 397.0K | 100.0K | — | — | — | — | 497.0K | 0.00% | ↗ |
| 29 | 2019 | Leslie Goldman Senior Vice President, General Counsel | 375.0K | 67.0K | — | — | — | — | 442.0K | 0.00% | ↗ |
| 30 | 2019 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 325.0K | 20.0K | — | — | — | — | 345.0K | 0.00% | ↗ |
| 31 | 2018 | Linda F. Powers Chairperson, President Chief Executive Officer | 502.0K | — | — | 6.70M | — | — | 7.20M | 93.03% | ↗ |
| 32 | 2018 | Leslie J. Goldman Senior Vice President, General Counsel | 375.0K | — | — | 4.19M | — | — | 4.56M | 91.78% | ↗ |
| 33 | 2018 | Leslie Goldman Senior Vice President, General Counsel | 375.0K | — | — | 4.19M | — | — | 4.56M | 91.78% | ↗ |
| 34 | 2018 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 325.0K | — | — | 1.53M | — | — | 1.85M | 82.46% | ↗ |
| 35 | 2018 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 375.0K | — | — | 260.0K | — | — | 635.0K | 40.94% | ↗ |
| 36 | 2018 | Susan Goldman* | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 37 | 2017 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 375.0K | — | — | 505.0K | — | — | 880.0K | 57.39% | ↗ |
| 38 | 2017 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 325.0K | — | — | 216.0K | — | — | 541.0K | 39.93% | ↗ |
| 39 | 2017 | Linda F. Powers Chairperson, President Chief Executive Officer | 502.0K | — | — | — | — | — | 502.0K | 0.00% | ↗ |
| 40 | 2017 | Leslie J. Goldman Senior Vice President, General Counsel | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 41 | 2017 | Leslie J. Goldman Senior Vice President, Business Development | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 42 | 2017 | Susan Goldman* | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 43 | 2016 | Linda F. Powers Chairperson, President Chief Executive Officer | 502.0K | — | — | — | — | — | 502.0K | 0.00% | ↗ |
| 44 | 2016 | Leslie J. Goldman Senior Vice President, General Counsel | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 45 | 2016 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 46 | 2016 | Leslie J. Goldman Senior Vice President, Business Development | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 47 | 2016 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 48 | 2016 | Susan Goldman* | 118.0K | — | — | — | — | — | 118.0K | 0.00% | ↗ |
| 49 | 2015 | Linda F. Powers Chairperson, President Chief Executive Officer | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
| 50 | 2015 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 51 | 2015 | Leslie J. Goldman Senior Vice President, Business Development | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 52 | 2015 | Leslie Goldman Senior Vice President, Business Development | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 53 | 2015 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 54 | 2014 | Linda F. Powers Chairperson, President Chief Executive Officer | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
| 55 | 2014 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 375.0K | 50.0K | — | — | — | — | 425.0K | 0.00% | ↗ |
| 56 | 2014 | Leslie Goldman Senior Vice President, Business Development | 375.0K | 50.0K | — | — | — | — | 425.0K | 0.00% | ↗ |
| 57 | 2014 | Marnix L. Bosch, Ph.D., M.B.A. Chief Technical Officer | 375.0K | 50.0K | — | — | — | — | 375.0K | 0.00% | ↗ |
| 58 | 2014 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 59 | 2013 | Linda F. Powers Chairperson, President | 360.0K | — | — | — | — | — | 360.0K | 0.00% | ↗ |
| 60 | 2013 | Linda F. Powers Chairperson, President Chief Executive Officer | 360.0K | — | — | — | — | — | 360.0K | 0.00% | ↗ |
| 61 | 2013 | Leslie Goldman Senior Vice President, | 348.0K | — | — | — | — | — | 348.0K | 0.00% | ↗ |
| 62 | 2013 | Leslie Goldman Senior Vice President, Business Development | 348.0K | — | — | — | — | — | 348.0K | 0.00% | ↗ |
| 63 | 2013 | Marnix L. Bosch, Ph.D., M.B.A. Chief Technical Officer | 325.2K | — | — | — | — | — | 325.2K | 0.00% | ↗ |
| 64 | 2013 | Marnix L. Bosch, Ph.D. Chief Technical Officer | 325.2K | — | — | — | — | — | 325.2K | 0.00% | ↗ |
| 65 | 2013 | Anthony Maida, Ph.D. Chief Operating Officer | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 66 | 2013 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 295.7K | — | — | — | — | — | 295.7K | 0.00% | ↗ |
| 67 | 2012 | Linda F. Powers Chairperson, President | 360.0K | — | — | — | — | — | 360.0K | 0.00% | ↗ |
| 68 | 2012 | Leslie Goldman Senior Vice President, | 348.0K | — | — | — | — | — | 348.0K | 0.00% | ↗ |
| 69 | 2012 | Marnix L. Bosch, Ph.D., M.B.A. Chief Technical Officer | 325.2K | — | — | — | — | — | 325.2K | 0.00% | ↗ |
| 70 | 2012 | Marnix L. Bosch, Ph.D., M.B.A. Chief Technical Officer | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 71 | 2012 | Anthony Maida, Ph.D. Chief Operating Officer | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 72 | 2012 | Alton L. Boynton, Ph.D. Chief Scientific Officer and | 295.7K | — | — | — | — | — | 295.7K | 0.00% | ↗ |
| 73 | 2012 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 295.0K | — | — | — | — | — | 295.0K | 0.00% | ↗ |
| 74 | 2011 | Linda F. Powers Chairperson, President | 203.3K | — | — | 9.26M | — | — | 9.47M | 97.85% | ↗ |
| 75 | 2011 | Alton L. Boynton, Ph.D. Chief Scientific Officer and Secretary | 334.7K | — | — | 1.55M | — | — | 1.88M | 82.22% | ↗ |
| 76 | 2011 | Leslie Goldman Senior Vice President, | 149.1K | — | — | 1.47M | — | — | 1.61M | 90.77% | ↗ |
| 77 | 2011 | Marnix L. Bosch, Ph.D., M.B.A. Chief Technical Officer | 339.4K | 20.0K | — | 1.19M | — | — | 1.55M | 76.85% | ↗ |
| 78 | 2011 | Anthony Maida, Ph.D. Chief Operating Officer | 160.4K | — | — | 814.2K | — | — | 974.6K | 83.54% | ↗ |
| 79 | 2008 | Alton L. Boynton, Ph.D. President, Chief Executive Officer, Chief Scientific Officer and Secretary | 331.3K | — | — | — | — | 504.00 | 331.8K | 0.00% | ↗ |
| 80 | 2008 | Marnix L. Bosch, Ph.D., M.B.A. Chief Technical Officer | 250.0K | — | — | — | — | 672.00 | 250.7K | 0.00% | ↗ |
| 81 | 2008 | Anthony P. Deasey Senior Vice President and Chief Financial Officer | 215.3K | — | — | — | — | 378.00 | 215.7K | 0.00% | ↗ |
| 82 | 2007 | Alton L. Boynton, Ph.D. President, Chief Executive Officer, Chief Scientific Officer and Secretary | 331.3K | — | — | 2.01M | — | 1.8K | 2.34M | 85.79% | ↗ |
| 83 | 2007 | Marnix L. Bosch, Ph.D., M.B.A. Chief Technical Officer | 225.0K | — | — | 471.7K | — | 482.00 | 697.1K | 67.66% | ↗ |
| 84 | 2007 | Anthony P. Deasey Senior Vice President and Chief Financial Officer | 63.5K | — | — | 115.3K | — | — | 178.7K | 64.49% | ↗ |
| 85 | 2007 | Linda F. Powers Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer | — | — | — | — | — | — | 61.0K | 0.00% | ↗ |
| 86 | 2007 | R. Steve Harris | — | — | — | — | — | — | 35.7K | 0.00% | ↗ |
| 87 | 2006 | Alton L. Boynton, Ph.D. President, Chief Executive Officer, Chief Scientific Officer and Secretary | 330.8K | — | — | — | — | 3.0K | 333.8K | 0.00% | ↗ |
| 88 | 2003 | Alton L.Boynton, Ph.D. president, chief operating officer, chief scientific officer | 289.0K | — | — | — | — | 294.9K | 583.9K | 0.00% | ↗ |
| 89 | 2003 | Daniel O.Wilds Former chairman of the board of directors, and, former chief executive officer | 159.2K | — | — | — | — | 314.8K | 474.0K | 0.00% | ↗ |
| 90 | 2003 | Eric Holmes, Ph.D. Former vice president of biomedical research and development | 127.1K | — | — | — | — | 65.8K | 192.9K | 0.00% | ↗ |
| 91 | 2003 | Marnix L.Bosch, Ph.D. vice president of vaccine research and development | 159.7K | — | — | — | — | 32.9K | 192.6K | 0.00% | ↗ |
| 92 | 2003 | Patricia A.Lodge, Ph.D. Former vice president of operations and process development | 132.7K | — | — | — | — | 20.5K | 153.2K | 0.00% | ↗ |
| 93 | 2002 | Daniel O. Wilds Chairman of the Board of Directors, President and Chief Executive Officer | 375.1K | — | — | — | — | 35.0K | 410.2K | 0.00% | ↗ |
| 94 | 2002 | Daniel O.Wilds Former chairman of the board of directors, and, former chief executive officer | 375.1K | — | — | — | — | 35.0K | 410.2K | 0.00% | ↗ |
| 95 | 2002 | Jim D. Johnston Former Executive Vice President, Chief Financial Officer and | 177.9K | — | — | — | — | 204.8K | 382.7K | 0.00% | ↗ |
| 96 | 2002 | Alton L.Boynton, Ph.D. president, chief operating officer, chief scientific officer | 331.3K | — | — | — | — | 43.5K | 374.8K | 0.00% | ↗ |
| 97 | 2002 | Alton L. Boynton, Ph.D. Executive Vice President, Chief Operating Officer, Chief | 331.3K | — | — | — | — | 43.5K | 374.8K | 0.00% | ↗ |
| 98 | 2002 | Scott C. Stromatt, M.D. Former Vice President, Chief Medical Officer | 111.5K | 109.8K | — | — | — | 98.7K | 320.0K | 0.00% | ↗ |
| 99 | 2002 | Eric Holmes, Ph.D. Vice President of Biomedical Research and Development | 188.5K | — | — | — | — | 29.0K | 217.6K | 0.00% | ↗ |
| 100 | 2002 | Eric Holmes, Ph.D. Former vice president of biomedical research and development | 188.5K | — | — | — | — | 29.0K | 217.6K | 0.00% | ↗ |
| 101 | 2002 | Patricia A. Lodge, Ph.D. Vice President of Operations and Process Development | 147.1K | — | — | — | — | 28.2K | 175.3K | 0.00% | ↗ |
| 102 | 2002 | Patricia A.Lodge, Ph.D. Former vice president of operations and process development | 147.1K | — | — | — | — | 28.2K | 175.3K | 0.00% | ↗ |
| 103 | 2002 | Marnix L.Bosch, Ph.D. vice president of vaccine research and development | 158.2K | — | — | — | — | 13.0K | 171.2K | 0.00% | ↗ |
| 104 | 2002 | Marnix L. Bosch, Ph.D. Vice President of Vaccine Research and Development | 158.2K | — | — | — | — | 13.0K | 171.2K | 0.00% | ↗ |
| 105 | 2001 | Daniel O.Wilds Former chairman of the board of directors, and, former chief executive officer | 299.0K | 135.0K | — | — | — | 10.3K | 444.3K | 0.00% | ↗ |
| 106 | 2001 | Daniel O. Wilds Chairman of the Board of Directors, President and Chief Executive Officer | 299.0K | 135.0K | — | — | — | 10.3K | 444.3K | 0.00% | ↗ |
| 107 | 2001 | Daniel O. Wilds Chairman of the Board of Directors, President and Chief Executive Officer | 299.0K | 135.0K | — | — | — | — | 434.0K | 0.00% | ↗ |
| 108 | 2001 | Alton L. Boynton, Ph.D. Executive Vice President, Chief Operating Officer, Chief | 265.0K | 92.8K | — | — | — | 14.5K | 372.2K | 0.00% | ↗ |
| 109 | 2001 | Alton L.Boynton, Ph.D. president, chief operating officer, chief scientific officer | 265.0K | 92.8K | — | — | — | 14.5K | 372.2K | 0.00% | ↗ |
| 110 | 2001 | Alton L. Boynton, Ph.D. President, Chief Executive Officer, Chief Scientific Officer and Secretary | 265.0K | 92.8K | — | — | — | — | 357.8K | 0.00% | ↗ |
| 111 | 2001 | Eric Holmes, Ph.D. Vice President of Biomedical Research and Development | 178.0K | 28.3K | — | — | — | 11.7K | 218.0K | 0.00% | ↗ |
| 112 | 2001 | Eric Holmes, Ph.D. Former vice president of biomedical research and development | 178.0K | 28.3K | — | — | — | 11.7K | 218.0K | 0.00% | ↗ |
| 113 | 2001 | Eric Holmes, Ph.D. Vice President of Biomedical Research and Development | 178.0K | 28.3K | — | — | — | — | 206.3K | 0.00% | ↗ |
| 114 | 2001 | Marnix L.Bosch, Ph.D. vice president of vaccine research and development | 137.9K | 21.8K | — | — | — | 9.3K | 169.0K | 0.00% | ↗ |
| 115 | 2001 | Marnix L. Bosch, Ph.D. Vice President of Vaccine Research and Development | 137.9K | 21.8K | — | — | — | 9.3K | 169.0K | 0.00% | ↗ |
| 116 | 2001 | Patricia A.Lodge, Ph.D. Former vice president of operations and process development | 130.0K | 21.0K | — | — | — | 8.8K | 159.8K | 0.00% | ↗ |
| 117 | 2001 | Patricia A. Lodge, Ph.D. Vice President of Operations and Process Development | 130.0K | 21.0K | — | — | — | 8.8K | 159.8K | 0.00% | ↗ |
| 118 | 2001 | Michael Salgaller, Ph.D. | 131.5K | 21.3K | — | — | — | — | 152.8K | 0.00% | ↗ |
| 119 | 2001 | Patricia A. Lodge, Ph.D. Vice President of Operations and Process Development | 130.0K | 21.0K | — | — | — | — | 151.0K | 0.00% | ↗ |
| 120 | 2001 | Scott C. Stromatt, M.D. Former Vice President, Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 121 | 2001 | Jim D. Johnston Former Executive Vice President, Chief Financial Officer and | — | — | — | — | — | — | — | — | ↗ |
| 122 | 2000 | Daniel O. Wilds Chairman of the Board of Directors, President and Chief Executive Officer | 250.0K | 87.5K | — | — | — | 10.4K | 347.9K | 0.00% | ↗ |
| 123 | 2000 | Alton L. Boynton, Ph.D. Executive Vice President, Chief Operating Officer, Chief | 229.9K | 61.0K | — | — | — | 14.7K | 305.6K | 0.00% | ↗ |
| 124 | 2000 | Eric Holmes, Ph.D. Vice President of Biomedical Research and Development | 170.1K | 18.3K | — | — | — | 11.6K | 200.0K | 0.00% | ↗ |
| 125 | 2000 | Patricia A. Lodge, Ph.D. Vice President of Operations and Process Development | 108.8K | 12.0K | — | — | — | 6.8K | 127.6K | 0.00% | ↗ |
| 126 | 2000 | Marnix L. Bosch, Ph.D. Vice President of Vaccine Research and Development | 71.9K | 15.0K | — | — | — | 2.8K | 89.7K | 0.00% | ↗ |
| 127 | 2000 | Jim D. Johnston Former Executive Vice President, Chief Financial Officer and | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2000 | Scott C. Stromatt, M.D. Former Vice President, Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Linda F. Powers | Chairperson, Chief Executive Officer, President, Chief Financial Officer & Chief Accounting Officer | 925.0K | female |
| Marnix L. Bosch | Chief Technical Officer | 632.8K | — |
| Alton L. Boynton | Founder, Chief Scientific Officer, Secretary & Director | 375.0K | — |
| David Innes | Vice President of Investor Relations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NWBO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
